Product Pathways - Jak/Stat Pathway
SignalSilence® Stat1 siRNA I #6331
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Western blot analysis of extracts from HeLa cells 48 hours following mock transfection, transfection with non-targeted (control) siRNA or transfection with Stat1 siRNA. Stat1 was detected using Stat1 Antibody #9172, and p42 was detected using p42 MAPK Antibody #9108. The Stat1 Antibody confirms silencing of Stat1 expression, and the p42 MAPK Antibody is used to control for protein loading and siRNA specificity.
SignalSilence® Stat1 siRNA allows the researcher to specifically inhibit Stat1 expression by RNA interference, a method in which gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce protein expression in specified cell lines.
Directions for Use
CST recommends transfection with 100 nM Stat1 siRNA. Decreased Stat1 expression was observed 24-72 hours post-transfection. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
The Stat1 transcription factor is activated in response to a large number of ligands (1) and is essential for responsiveness to IFN-α and IFN-γ (2,3). Phosphorylation of Stat1 at Tyr701 induces Stat1 dimerization, nuclear translocation, and DNA binding (4). Stat1 protein exists as a pair of isoforms, Stat1α (91 kDa) and the splice variant Stat1β (84 kDa). In most cells, both isoforms are activated by IFN-α, but only Stat1α is activated by IFN-γ. The inappropriate activation of Stat1 occurs in many tumors (5). In addition to tyrosine phosphorylation, Stat1 is also phosphorylated at Ser727 through a p38 mitogen-activated protein kinase (MAPK)-dependent pathway in response to IFN-α and other cellular stresses (6). Serine phosphorylation may be required for the maximal induction of Stat1-mediated gene activation.
- Heim, M.H. (1999) J. Recept. Signal. Transduct. Res. 19, 75-120.
- Durbin, J.E. et al. (1996) Cell 84, 443-450.
- Meraz, M.A. et al. (1996) Cell 84, 431-442.
- Ihle, J.N. et al. (1994) Trends Biochem. Sci. 19, 222-227.
- Frank, D.A. (1999) Mol. Med. 5, 432-456.
- Wen, Z. et al. (1995) Cell 82, 241-250.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 6544 SignalSilence® Stat1 siRNA II
- 9172 Stat1 Antibody
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.
For Research Use Only. Not For Use In Diagnostic Procedures.